Pharma Pulse 2/3/25: The Rundown on Rebates, GLP-1s and Pharmacists' Role & more

The Rundown on Rebates

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld value & access advisor for Schoonveld Advisory and author of The Price of Global Health, previews his upcoming February column.

GLP-1 Medications and Pharmacists' Role in Counseling Patients

Donna Ryan, MD discusses GLP-1 medications and new developments on the horizon, while providing some best practices for patients initiating treatment, including important nutritional and lifestyle changes.

New Pain Drug Gets FDA Nod as Safer Alternative to Addictive Opioids

Vertex Pharmaceuticals Inc. gained US approval for the first new type of painkiller in more than two decades, paving the way for a safer alternative to addictive opioids that have been linked to hundreds of thousands of deaths.

GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand

GE HealthCare has announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand.

UpScriptHealth on LinkedIn

In a recent interview with Pharmaceutical Executive, our founder & CEO Peter Ax discussed the risks associated with obtaining compounded medications. He shares, "These are not the branded drugs being manufactured in FDA facilities. They're being manufactured in compounding pharmacies, which are licensed and are inspected, but there's certainly more of a risk when you purchase a drug that is compounded than when it is manufactured in an FDA approved facility."

#FDA #drugsafety #compoundeddrugs

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs